A new pivotal trial readout for Abbott’s Amulet 360 left atrial appendage (LAA) occluder has revealed compelling one-year data, showcasing exceptional LAA closure rates and a significant reduction in stroke risk for patients with atrial fibrillation (AFib) who are unsuitable for long-term anticoagulation therapy. The findings, presented at a major cardiovascular conference and published in a leading medical journal, underscore the potential of this next-generation device to expand treatment options and improve outcomes for a vulnerable patient population.
Breakthrough in Stroke Prevention: The Amulet 360’s Impact on AFib Patients
Atrial fibrillation (AFib), a common heart rhythm disorder, significantly increases the risk of stroke. A primary culprit in AFib-related strokes is the formation of blood clots within the left atrial appendage (LAA), a small, ear-shaped pouch in the left atrium of the heart. For patients who cannot tolerate or are contraindicated for traditional blood-thinning medications (anticoagulants), the risk of stroke remains a critical concern. Abbott’s Amulet 360 occluder offers a promising alternative by mechanically sealing off the LAA, thereby preventing clot formation and reducing stroke incidence.
The recent VERITAS (NCT06707688) pivotal study, a crucial clinical trial designed to assess the safety and efficacy of the Amulet 360, has yielded highly encouraging one-year results. The study focused on patients with AFib not caused by heart valve issues, a population where the LAA is a well-established source of embolic events. The data revealed that the Amulet 360 achieved complete closure of the LAA in an impressive 96.3% of these patients. Furthermore, over 98% of participants remained free from ischemic stroke or complications related to blood clots throughout the one-year follow-up period. These statistics represent a significant advancement in stroke risk mitigation for this challenging patient group.
A Deeper Dive into the VERITAS Trial Findings
The comprehensive one-year data from the VERITAS study, presented during a late-breaking session at the 2026 Transcatheter Cardiovascular Therapeutics (TCT) conference in California, provided a robust evaluation of the Amulet 360’s performance. The findings were simultaneously published in the esteemed journal, JACC: Cardiovascular Interventions, lending further weight to their clinical significance.
Beyond the primary endpoints of LAA closure and stroke prevention, the study also reported on other critical safety and efficacy measures. Notably, over 99% of patients were free from pericardial effusion, a potential complication where fluid accumulates around the heart, which is a key safety consideration for LAA closure procedures. Moreover, an overwhelming 98% of patients were free from cardiovascular-related mortality at the one-year mark, highlighting the overall positive impact of the treatment on patient survival and well-being.
These results are particularly impactful given the inherent risks associated with AFib. For individuals who cannot take anticoagulants due to factors such as bleeding disorders, a history of hemorrhagic stroke, or planned surgical procedures, LAA closure represents a vital therapeutic avenue. The durability of closure and the sustained freedom from stroke demonstrated by the Amulet 360 in the VERITAS trial offer a much-needed solution for these patients, potentially transforming their quality of life and reducing the burden of stroke.
The Science Behind Amulet 360: Engineering for Optimal Closure
The Amulet 360 occluder is engineered with advanced technology designed to facilitate effective and durable LAA closure. At its core, the device employs a dual-seal mechanism, comprising two interconnected nitinol metal mesh components. This innovative design is intended to conform to the unique anatomy of the LAA, ensuring a secure and complete seal.
Nitinol, a nickel-titanium alloy, is chosen for its superelastic properties, allowing the device to be compressed for delivery through a catheter and then expand to conform to the LAA’s shape. The dual-seal mechanism is a key differentiator, aiming to provide enhanced sealing capabilities and minimize the potential for residual leaks, which could compromise the device’s effectiveness in preventing clot formation. This intricate engineering is crucial for achieving the high closure rates observed in the VERITAS trial.
Official Responses: Confidence in Next-Generation Technology
The robust performance of the Amulet 360 has elicited strong positive responses from key figures within Abbott and the broader cardiovascular community. Christopher Piorkowski, Chief Medical Officer for Abbott’s electrophysiology business, expressed his enthusiasm for the VERITAS results.
"Amulet 360 was designed with enhanced conformability and sealing features intended to support durable closure across a wider range of anatomies," stated Piorkowski. "The one-year VERITAS results reinforce the potential of these next-generation enhancements to expand patient choice and help physicians confidently offer left atrial appendage closure to patients at the right time in their care journey."
His comments highlight the deliberate design considerations behind the Amulet 360, emphasizing its adaptability to diverse LAA anatomies, a common challenge in LAA closure procedures. The device’s improved conformability aims to overcome limitations of previous generations, enabling more physicians to successfully treat a broader spectrum of patients.
Echoing this sentiment, DJ Lakkireddy, Executive Medical Director of the Kansas City Heart Rhythm Institute and lead author on the JACC publication, underscored the clinical significance of the findings. "The VERITAS trial results are highly encouraging, demonstrating high rates of complete closure sustained through 12 months," Lakkireddy remarked. "These findings reinforce the potential of the Amulet 360 technology to provide physicians with an effective treatment option as we continue to advance strategies for stroke risk reduction in this patient population."
The affirmation from a leading investigator involved in the trial provides further validation of the Amulet 360’s efficacy and its role in the evolving landscape of stroke prevention strategies for AFib patients.
Chronology of Development and Market Entry
Abbott’s journey in the LAA closure space has been marked by continuous innovation. The Amulet 360 represents the evolution of their previous Amplatzer occluder devices, building upon years of clinical experience and technological refinement.
The Amulet implant, the predecessor to the Amulet 360, secured a crucial CE mark in Europe in August 2026, signaling its regulatory approval and availability in the European market. This marked a significant milestone for Abbott, allowing them to offer this advanced LAA closure technology to patients across Europe.
Currently, the Amulet 360 is pending clearance from the U.S. Food and Drug Administration (FDA). The positive data from the VERITAS pivotal trial is expected to significantly bolster Abbott’s submission to the FDA, paving the way for its eventual availability to the U.S. patient population. The device’s design is specifically noted to be softer and more conformable than its predecessor, the Amplatzer, which is crucial for accommodating a wider array of LAA shapes and facilitating successful implantation.
Market Implications and Future Outlook
The global market for Left Atrial Appendage (LAA) closure devices is experiencing robust growth, driven by an increasing awareness of AFib’s stroke risk and the demand for alternative treatment options. GlobalData analysis indicates a compound annual growth rate (CAGR) of 8.5% for this market, with projections suggesting a valuation of nearly $6 billion by 2035, more than doubling its value from 2025.
This expanding market presents a significant opportunity for Abbott. Currently, Boston Scientific holds a dominant position in the U.S. LAA closure device market, largely attributed to its well-established Watchman device. According to GlobalData models, Boston Scientific commanded an impressive 80% share of the U.S. market in 2025. Abbott followed with an 11.7% share, and AtriCure held 4.1%.
The introduction of the Amulet 360, with its enhanced features and the compelling evidence from the VERITAS trial, has the potential to disrupt this market dynamic. By offering a potentially superior device in terms of conformability and sealing efficacy, Abbott could capture a larger share of the market, particularly among patients with more complex LAA anatomies. Furthermore, as the overall market expands, Abbott’s ability to offer a differentiated and effective solution will be critical for its sustained growth and competitive positioning.
The success of the Amulet 360 in reducing stroke risk for AFib patients unsuitable for anticoagulation is a testament to ongoing advancements in cardiovascular device technology. The data from the VERITAS trial not only validates the efficacy of this next-generation occluder but also underscores the growing importance of LAA closure as a cornerstone of stroke prevention strategies for a significant and often underserved patient population. As the device awaits FDA clearance, the medical community eagerly anticipates its broader availability, which promises to expand treatment choices and ultimately improve the lives of countless individuals living with AFib.
About the Author
